echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA awarded NT102 the title of orphan drug for the treatment of Dravet syndrome

    FDA awarded NT102 the title of orphan drug for the treatment of Dravet syndrome

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dravet syndrome is a rare childhood syndrome that affects 1 in 15,700 babies born in the United States and is characterized by encephalopathy and epilepsy
    .


    It is difficult to diagnose because many symptoms are not obvious in the first year after the child is born


    Children's Epilepsy Diagnostic Fund
    • Have normal or near-normal cognitive and motor development before epileptic seizure


      Neuroene Therapeutics recently announced that the FDA has granted the company's proprietary compound NT102 the orphan drug designation
      .


      NT102 was developed as a mitochondrial and neuroprotective substance for the treatment of neurological diseases, such as drug-resistant epilepsy


      FDA NT102 has a wide range of seizure protection in a variety of preclinical animal models, especially for the epileptic seizures of Dravet syndrome (a rare childhood syndrome characterized by severe encephalopathy and epilepsy)


      Original source:

      Original source:

      https:// href="https://" target="_blank" rel="noopener">https:// https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.